ATE503757T1 - Kondensierte imidazole zur krebsbehandlung - Google Patents

Kondensierte imidazole zur krebsbehandlung

Info

Publication number
ATE503757T1
ATE503757T1 AT08787222T AT08787222T ATE503757T1 AT E503757 T1 ATE503757 T1 AT E503757T1 AT 08787222 T AT08787222 T AT 08787222T AT 08787222 T AT08787222 T AT 08787222T AT E503757 T1 ATE503757 T1 AT E503757T1
Authority
AT
Austria
Prior art keywords
cancer treatment
condensed imidazoles
imidazoles
condensed
cancer
Prior art date
Application number
AT08787222T
Other languages
English (en)
Inventor
Swen Hoelder
Armin Zuelch
Thomas Baer
Thomas Maier
Astrid Zimmermann
Thomas Beckers
Volker Gekeler
Hemant Joshi
Yogesh Munot
Umesh Bhise
Sunil Chavan
Sachin Shivatare
Sarvesh Patel
Vikas Gore
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07118733A external-priority patent/EP2062893A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE503757T1 publication Critical patent/ATE503757T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT08787222T 2007-08-14 2008-08-14 Kondensierte imidazole zur krebsbehandlung ATE503757T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1573MU2007 2007-08-14
EP07118733A EP2062893A1 (de) 2007-10-18 2007-10-18 Fusionierte Imidazole zur Behandlung von Krebs
PCT/EP2008/060686 WO2009021990A1 (en) 2007-08-14 2008-08-14 Fused imidazoles for cancer treatment

Publications (1)

Publication Number Publication Date
ATE503757T1 true ATE503757T1 (de) 2011-04-15

Family

ID=39876840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08787222T ATE503757T1 (de) 2007-08-14 2008-08-14 Kondensierte imidazole zur krebsbehandlung

Country Status (24)

Country Link
US (2) US8592591B2 (de)
EP (1) EP2176259B1 (de)
JP (1) JP5327652B2 (de)
KR (1) KR20100049589A (de)
CN (1) CN101835776A (de)
AR (1) AR067946A1 (de)
AT (1) ATE503757T1 (de)
AU (1) AU2008288390A1 (de)
CA (1) CA2695251C (de)
CL (1) CL2008002397A1 (de)
CR (1) CR11271A (de)
DE (1) DE602008005894D1 (de)
DO (1) DOP2010000057A (de)
EA (1) EA201000297A1 (de)
EC (1) ECSP109965A (de)
MA (1) MA31609B1 (de)
MX (1) MX2010001745A (de)
PA (1) PA8793301A1 (de)
PE (1) PE20090596A1 (de)
SV (1) SV2010003482A (de)
TN (1) TN2010000071A1 (de)
TW (1) TW200924761A (de)
UY (1) UY31292A1 (de)
WO (1) WO2009021990A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573357B (zh) * 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
CA2695251C (en) * 2007-08-14 2016-06-21 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US20130310362A1 (en) * 2009-02-13 2013-11-21 Bayer Pharma Aktiegesellschaft Fused pyrimidines
CA2755285C (en) 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibitors of pi3 kinase
WO2010125799A1 (ja) 2009-04-27 2010-11-04 塩野義製薬株式会社 Pi3k阻害活性を有するウレア誘導体
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
CA2778265A1 (en) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
CA2787714C (en) * 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2804845A1 (en) * 2010-07-12 2012-01-19 Stuart Ince Substituted imidazo[1,2-a]pyrimidines and -pyridines
JP5926727B2 (ja) 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾ［１，２−ｂ］ピリダジン
EP2463289A1 (de) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]Pyridazin-Derivate als AS JAK-Hemmer
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
CN103459400B (zh) * 2011-04-06 2016-05-18 大鹏药品工业株式会社 咪唑并噁嗪化合物或其盐
MX336865B (es) 2011-04-07 2016-02-04 Bayer Pharma AG Imidazopiridazinas como inhibidores de quinasa akt.
JP6115962B2 (ja) 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ．ベー． １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体
EP2554544A1 (de) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1H-)-on-Derivate als JAK-Inhibitoren
EP2802588B1 (de) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituierte pyrazolopyrimidine als akt kinase-inhibitore
CA2860723A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
WO2014007217A1 (ja) * 2012-07-02 2014-01-09 大鵬薬品工業株式会社 イミダゾオキサジン化合物による抗腫瘍効果増強剤
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
EP2976086B1 (de) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Kombination aus katalytischen mtorc 1/2-inhibitoren und selektiven inhibitoren der aurora-a-kinase
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN107428779A (zh) 2015-02-27 2017-12-01 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3529245A4 (de) * 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. Verbindungen und verwendungen davon
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3801069A4 (de) 2018-06-01 2022-03-16 Cornell University Kombinationstherapie für eine pi3k-assoziierte erkrankung oder störung
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN118812530B (zh) * 2023-04-18 2026-02-13 中国科学院大连化学物理研究所 一种Pd/C双组分体系催化木质素及模型化合物制备咪唑吡啶类化合物的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249679A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
EP1277754B8 (de) * 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridin-derivate
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP2007500160A (ja) * 2003-07-30 2007-01-11 ラボラトリオス・エセ・ア・エレ・ベ・ア・テ・ソシエダッド・アノニマ 癌の予防および治療のための置換イミダゾピリミジン
CA2561311A1 (en) * 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
JP2008524339A (ja) * 2004-12-15 2008-07-10 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性のインヒビター
US7566716B2 (en) 2005-05-20 2009-07-28 Array Biopharma Inc. Imidazopyrazines as Raf inhibitor compounds
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
EP1928237A4 (de) * 2005-09-02 2011-03-09 Abbott Lab Neue heterocyclen auf imidazo-basis
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
CA2695251C (en) * 2007-08-14 2016-06-21 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment

Also Published As

Publication number Publication date
ECSP109965A (es) 2010-03-31
CN101835776A (zh) 2010-09-15
JP2010535847A (ja) 2010-11-25
AR067946A1 (es) 2009-10-28
PA8793301A1 (es) 2009-04-23
EA201000297A1 (ru) 2010-08-30
KR20100049589A (ko) 2010-05-12
JP5327652B2 (ja) 2013-10-30
DOP2010000057A (es) 2010-04-15
CA2695251C (en) 2016-06-21
EP2176259B1 (de) 2011-03-30
US9387204B2 (en) 2016-07-12
EP2176259A1 (de) 2010-04-21
UY31292A1 (es) 2009-03-31
US8592591B2 (en) 2013-11-26
MA31609B1 (fr) 2010-08-02
SV2010003482A (es) 2010-07-06
MX2010001745A (es) 2010-03-10
CA2695251A1 (en) 2009-02-19
TW200924761A (en) 2009-06-16
AU2008288390A1 (en) 2009-02-19
CL2008002397A1 (es) 2009-09-25
CR11271A (es) 2010-05-19
US20090156604A1 (en) 2009-06-18
TN2010000071A1 (en) 2011-09-26
DE602008005894D1 (de) 2011-05-12
PE20090596A1 (es) 2009-06-07
WO2009021990A1 (en) 2009-02-19
US20140088110A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
DE602008005894D1 (de) Kondensierte imidazole zur krebsbehandlung
BRPI0810206A2 (pt) Método de tratar câncer
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
BR112012005594A2 (pt) tratamento de câncer
DK3289876T3 (da) Forbindelser til behandling af cancer
EP3858416C0 (de) Kathetersystem
DK2121139T3 (da) Formulations for cancer treatment
ZA201003938B (en) Immersion treatment system
IL219715A (en) Sewage treatment apparatus
BRPI0817609A2 (pt) Derivados de imidazol
BRPI0912683A2 (pt) tratamento de tumores metastáticos
BR112012002797A2 (pt) tratamento de câncer de próstata
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0818855A2 (pt) Derivados de imidazol
HUE038563T2 (hu) Rák kezelési eljárás
SE0702686L (sv) Förfarande för säkra transaktioner
BRPI0818863A2 (pt) Derivados de imidazol
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BR112012003653A2 (pt) "método de tratar o câncer."
PT3388111T (pt) Composto organoarsénico para o tratamento de cancro
BRPI0913872A2 (pt) multi-bandagem
ATE446292T1 (de) Heterocyclylamid-substituierte imidazole
BRPI0916970A2 (pt) Combinações de imidazol substituído
GB0707556D0 (en) Treatment for cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties